Going concern and liquidity risk
Management states it has incurred significant losses and expects additional losses, with plans dependent on raising new capital.
- Scope
- Cash runway and financing access
- Materiality
- high
Clene Inc.
Clene Inc. is a U.S.-based pharmaceutical preparations company that also sells dietary mineral supplements through its subsidiary and commercial partners. The company’s reported revenue is currently small and comes mainly from sales of Zinc Factor, Gold Factor, and rMetx ZnAg Immune Boost, while most of its resources remain focused on research and development of drug candidates.
−10 794,0 %
78,5 %
−13 086,5 %
−41,5 %
0.83
0.83
| % | |
|---|---|
| Dietary mineral supplements | 100% Aqueous zinc-silver and gold mineral supplement products sold directly or through 4Life. |
| Royalty revenue | 0% License-based royalties tied to Gold Factor sales under an exclusive agreement with 4Life. |
| Drug candidate development | 0% Research and development programs aimed at advancing Clene’s therapeutic pipeline. |
Clene sells its supplement products through a mix of direct subsidiary sales and a commercial supply/license...
- 4Life commercial partnerprimary
Buys Zinc Factor and Gold Factor under supply and license arrangements and drives most current product and royalty revenue.
- Direct supplement buyerssecondary
Purchasers of rMetx ZnAg Immune Boost through Clene’s wholly owned subsidiary.
- Future pharmaceutical end marketsemerging
Potential future patients, prescribers, and healthcare systems for Clene’s drug candidates.
Clene is incorporated in Delaware and operates with subsidiaries in Australia and the Netherlands, reflecting a small...
- •Headquartered and incorporated in the United States
- •Subsidiaries in Australia and the Netherlands support operations
- •No country-level revenue disclosure was provided in the excerpts
- •Australia generated R&D tax credits, not operating revenue
- •Nasdaq listing creates U.S. capital market exposure
Clene’s near-term strategy is to preserve liquidity while continuing to develop its drug candidates and maintain...
01
Liquidity preservation and financingshort-term
The company has recurring losses and substantial doubt about going concern, so funding is essential to continue operations.
02
Cost reductionshort-term
Lowering cash burn extends runway while the company seeks external capital and advances its pipeline.
03
Pipeline developmentmedium-term
Long-term value depends on converting R&D into viable therapeutic products beyond the current supplement business.
Clene faces acute financing and listing risk because it has sustained losses, negative operating cash flow, and a...
Nasdaq delisting risk
The company received a notice that its market value of listed securities was below the minimum requirement and may be delisted if it does not regain compliance.
- Scope
- Nasdaq continued listing requirements
- Materiality
- high
Customer and partner concentration
Current revenue depends heavily on 4Life-related supply and license arrangements and timing of purchases.
- Scope
- Product and royalty revenue
- Materiality
- high
Development and regulatory execution risk
Future value depends on advancing drug candidates through research, development, and eventual commercialization.
- Scope
- Pipeline programs
- Materiality
- high
Revenue recognition for supply and royalty agreements
Affects reported revenue and comparability across periods
Fair value of warrants and derivative liabilities
Can materially affect net income without changing cash flow
Convertible notes and contingent earn-out liabilities
Affects liabilities, interest/other income, and dilution analysis
Deferred tax asset valuation allowance
Limits recognition of tax benefits and signals ongoing losses
: 28.4.2026